Tracon Pharmaceuticals, Inc. Overview
Pro stress-test →Tracon Pharmaceuticals was a biopharmaceutical company focused on developing targeted cancer therapeutics, including antibody-based treatments and immunotherapy candidates. The company has ceased operations following the failure of its lead program and subsequent dissolution.
Strategic Profile
Pro stress-test →The company developed anti-endoglin antibodies and PD-L1 inhibitor candidates for oncology applications including sarcoma, renal cell carcinoma, and glioblastoma. After clinical trial setbacks in mid-2024, the company pursued liquidation rather than strategic alternatives.
Competitive Landscape
Pro stress-test →Prior to dissolution, Tracon competed with Jazz Pharmaceuticals, Sana Biotechnology, and Kite Pharma in immuno-oncology and antibody therapeutics. The company's narrow focus on a single lead candidate left it vulnerable to clinical setbacks.
Industry Context
Tracon Pharmaceuticals, Inc. operates in Cancer immunotherapy.
Key facts
Founded: 2004 · Headquarters: San Diego, US · Employees: 0 (all terminated July 31, 2024) · Revenue: $3.2M (TTM as of Q2 2024) · Market cap: N/A (dissolved)